Therapeuticpreclinical
Biosimilar Trastuzumab
Originator: Herceptin (Genentech/Roche)
High-yield CHO-expressed biosimilar of Trastuzumab (Herceptin) for HER2-positive cancers, developed under BIRAC-DBT funding.
Indications
- HER2-positive breast cancer
- HER2-positive gastric cancer
Overview
IMGENEX India is developing a biosimilar of Trastuzumab (Herceptin) using a proprietary high-expression CHO mammalian cell line capable of producing 3-4 g per liter. The program is supported by grants from BIRAC and DBT under the BIPP and BIRAC schemes.
Process Highlights
- Proprietary high-expression plasmid vector
- CHO mammalian expression system
- Bioprocess optimisation under BIRAC Phase II grant
- Targeted at affordability for emerging markets
Contact us today to learn more about this product. You can also email us at info@imgenexindia.com.